Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel

E. Quaquarini, D. D'Ambrosio, F. Sottotetti, F. Gallivanone, M. Hodolic, P. Baiardi, R. Palumbo, C. Vellani, C. Canevari, A. Bernardo, I. Castiglioni, C. Porta, G. Trifirò,

. 2019 ; 2019 (-) : 4325946. [pub] 20190326

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025904

Background and Aim: The availability of new treatments for metastatic castrate-resistant prostate cancer (mCRPC) patients increases the need for reliable biomarkers to help clinicians to choose the better sequence strategy. The aim of the present retrospective and observational work is to investigate the prognostic value of 18F-fluorocholine (18F-FCH) positron emission tomography (PET) parameters in mCRPC. Materials and Methods: Between March 2013 and August 2016, 29 patients with mCRPC were included. They all received three-weekly docetaxel after androgen deprivation therapy, and they underwent 18F-FCH PET/computed tomography (CT) before and after the therapy. Semi-quantitative indices such as maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean) with partial volume effect (PVC-SUV) correction, metabolically active tumour volume (MATV), and total lesion activity (TLA) with partial volume effect (PVC-TLA) correction were measured both in pre-treatment and post-treatment 18F-FCH PET/CT scans for each lesion. Whole-body indices were calculated as sum of values measured for each lesion (SSUVmax, SPVC-SUV, SMATV, and STLA). Progression-free survival (PFS) and overall survival (OS) were considered as clinical endpoints. Univariate and multivariate hazard ratios for whole-body 18F-FCH PET indices were performed, and p < 0.05 was considered as significant. Results: Cox regression analysis showed a statistically significant correlation between PFS, SMATV, and STLA. No correlations between OS and 18F-FCH PET parameters were defined probably due to the small sample size. Conclusions: Semi-quantitative indices such as SMATV and STLA at baseline have a prognostic role in patients treated with docetaxel for mCRPC, suggesting a potential role of 18F-FCH PET/CT imaging in clinical decision-making.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025904
003      
CZ-PrNML
005      
20201222154142.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2019/4325946 $2 doi
035    __
$a (PubMed)31049043
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Quaquarini, E $u Medical Oncology Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy. University of Pavia, Ph.D. in Experimental Medicine, Pavia 27100, Italy.
245    10
$a Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel / $c E. Quaquarini, D. D'Ambrosio, F. Sottotetti, F. Gallivanone, M. Hodolic, P. Baiardi, R. Palumbo, C. Vellani, C. Canevari, A. Bernardo, I. Castiglioni, C. Porta, G. Trifirò,
520    9_
$a Background and Aim: The availability of new treatments for metastatic castrate-resistant prostate cancer (mCRPC) patients increases the need for reliable biomarkers to help clinicians to choose the better sequence strategy. The aim of the present retrospective and observational work is to investigate the prognostic value of 18F-fluorocholine (18F-FCH) positron emission tomography (PET) parameters in mCRPC. Materials and Methods: Between March 2013 and August 2016, 29 patients with mCRPC were included. They all received three-weekly docetaxel after androgen deprivation therapy, and they underwent 18F-FCH PET/computed tomography (CT) before and after the therapy. Semi-quantitative indices such as maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean) with partial volume effect (PVC-SUV) correction, metabolically active tumour volume (MATV), and total lesion activity (TLA) with partial volume effect (PVC-TLA) correction were measured both in pre-treatment and post-treatment 18F-FCH PET/CT scans for each lesion. Whole-body indices were calculated as sum of values measured for each lesion (SSUVmax, SPVC-SUV, SMATV, and STLA). Progression-free survival (PFS) and overall survival (OS) were considered as clinical endpoints. Univariate and multivariate hazard ratios for whole-body 18F-FCH PET indices were performed, and p < 0.05 was considered as significant. Results: Cox regression analysis showed a statistically significant correlation between PFS, SMATV, and STLA. No correlations between OS and 18F-FCH PET parameters were defined probably due to the small sample size. Conclusions: Semi-quantitative indices such as SMATV and STLA at baseline have a prognostic role in patients treated with docetaxel for mCRPC, suggesting a potential role of 18F-FCH PET/CT imaging in clinical decision-making.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antagonisté androgenů $x aplikace a dávkování $7 D000726
650    _2
$a cholin $x aplikace a dávkování $x analogy a deriváty $x chemie $7 D002794
650    _2
$a docetaxel $x aplikace a dávkování $x chemie $7 D000077143
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multimodální zobrazování $x metody $7 D064847
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a PET/CT $x metody $7 D000072078
650    _2
$a prognóza $7 D011379
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a nádory prostaty rezistentní na kastraci $x diagnostické zobrazování $x farmakoterapie $x patologie $7 D064129
650    _2
$a radioisotopová scintigrafie $x metody $7 D011877
650    _2
$a tumor burden $x účinky léků $7 D047368
655    _2
$a časopisecké články $7 D016428
700    1_
$a D'Ambrosio, D $u Medical Physics Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy.
700    1_
$a Sottotetti, F $u Medical Oncology Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy.
700    1_
$a Gallivanone, F $u Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Milan 20090, Italy.
700    1_
$a Hodolic, M $u Nuclear Medicine Research Department, Iason, Graz, Austria. Nuclear Medicine Department, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.
700    1_
$a Baiardi, P $u Scientific Direction, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy.
700    1_
$a Palumbo, R $u Medical Oncology Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy.
700    1_
$a Vellani, C $u Nuclear Medicine Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy.
700    1_
$a Canevari, C $u Nuclear Medicine Unit, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.
700    1_
$a Bernardo, A $u Medical Oncology Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy.
700    1_
$a Castiglioni, I $u Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Milan 20090, Italy.
700    1_
$a Porta, C $u Translational Oncology Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy. University of Pavia, Department of Internal Medicine, Pavia 27100, Italy.
700    1_
$a Trifirò, G $u Nuclear Medicine Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy.
773    0_
$w MED00180205 $t Contrast media & molecular imaging $x 1555-4317 $g Roč. 2019, č. - (2019), s. 4325946
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31049043 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222154138 $b ABA008
999    __
$a ok $b bmc $g 1600049 $s 1116590
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 2019 $c - $d 4325946 $e 20190326 $i 1555-4317 $m Contrast Media Mol Imaging $n Contrast Media Mol Imaging $x MED00180205
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace